Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Journey Strategic Wealth LLC

Journey Strategic Wealth LLC lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,913 shares of the biopharmaceutical company’s stock after purchasing an additional 288 shares during the period. Journey Strategic Wealth LLC’s holdings in Gilead Sciences were worth $546,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in GILD. Avior Wealth Management LLC boosted its holdings in Gilead Sciences by 1.2% in the 3rd quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company’s stock valued at $782,000 after purchasing an additional 108 shares during the last quarter. Southland Equity Partners LLC grew its position in Gilead Sciences by 3.6% in the fourth quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company’s stock worth $289,000 after acquiring an additional 110 shares during the period. Concord Asset Management LLC VA grew its position in Gilead Sciences by 3.8% in the third quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company’s stock worth $256,000 after acquiring an additional 111 shares during the period. Berkshire Bank raised its position in Gilead Sciences by 3.4% in the fourth quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company’s stock valued at $314,000 after purchasing an additional 111 shares during the period. Finally, TFB Advisors LLC lifted its stake in shares of Gilead Sciences by 1.2% in the 3rd quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company’s stock valued at $788,000 after purchasing an additional 116 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 164,211 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the sale, the insider now directly owns 80,801 shares of the company’s stock, valued at $7,427,227.92. This trade represents a 67.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the sale, the chief financial officer now owns 129,873 shares of the company’s stock, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 456,234 shares of company stock worth $42,130,461 in the last quarter. 0.16% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of brokerages recently issued reports on GILD. Leerink Partnrs raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. Mizuho boosted their price target on shares of Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a research note on Thursday, November 21st. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $84.00 price objective on shares of Gilead Sciences in a research report on Wednesday, December 11th. Oppenheimer boosted their target price on Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. Finally, Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Thursday, November 7th. Eleven analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $98.39.

Gilead Sciences Stock Up 0.3 %

Shares of NASDAQ:GILD opened at $97.20 on Monday. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The firm has a 50 day simple moving average of $92.42 and a 200-day simple moving average of $85.87. The company has a market capitalization of $121.14 billion, a PE ratio of 1,080.00, a P/E/G ratio of 1.34 and a beta of 0.18. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter in the prior year, the firm posted $2.29 earnings per share. Gilead Sciences’s revenue for the quarter was up 7.0% on a year-over-year basis. On average, equities analysts predict that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.